Description
The RR4-7 antibody specifically reacts with the Vβ 6 T-Cell Receptor (TCR) of mice having the a (e.g., C57BR, C57L, SJL) and b (e.g., A, BALB/c, CBA/Ca, C3H/He, C57BL, DBA/1) haplotypes of the Tcrb gene complex. The Tcrb-V6 gene locus is deleted in mice having the c (e.g., RIII) haplotype. Vβ 6 TCR-bearing T lymphocytes are clonally eliminated in mice expressing superantigen encoded by Mtv-7 (Mls-1[a], Mls[a]) endogenous provirus (e.g., AKR, CBA/J, C58, DBA/2, NZB), or Mtv-43 endogenous provirus (e.g., MA/MyJ). Exogenous MMTV-SW, as well as endogenous Mtv-44-encoded superantigen (e.g., NZW), also causes incomplete elimination of Vβ 6 TCR-expressing T cells. Plate-bound RR4-7 antibody activates Vβ 6 TCR-bearing T cells, soluble RR4-7 mAb blocks in vitro proliferation and cytolytic activities of Vβ 6 TCR-bearing T-cell clones, and injection of the antibody results in in vivo depletion of Vβ 6 TCR-bearing T cells.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
1. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
4. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
5. An isotype control should be used at the same concentration as the antibody of interest.
6. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
7. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
10. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
11. For U.S. patents that may apply, see bd.com/patents.
